Molecular diagnostics firm Myriad Genetics has introduced its EndoPredict test in the US for patients with ER+ HER2- early-stage breast cancer.

EndoPredict is a second-generation, multigene test designed to predict the ten year risk of disease recurrence after surgery and determine the patients who can safely drop adjuvant chemotherapy.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The test provides information to establish personalised treatment plans for the patients.

Myriad Genetic Laboratories chief medical officer Johnathan Lancaster said: "Breast cancer is a complicated disease and there is a critical need for accurate breast cancer recurrence tests that help physicians determine which patients can safely forgo adjuvant chemotherapy.

"By automatically incorporating clinical features and generating an individualised patient test result, EndoPredict identifies a larger subset of true low-risk patients who may safely forgo adjuvant chemotherapy."

EndoPredict showed positive outcome in several prospective clinical trials conducted in more than 3,500 patients with ER+ HER2- node negative and node positive early-stage breast cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The results from the clinical development programme indicated that EndoPredict performs better than the first generation breast cancer recurrence tests.

"By automatically incorporating clinical features and generating an individualised patient test result, EndoPredict identifies a larger subset of true low-risk patients who may safely forgo adjuvant chemotherapy."

Using 10-year outcomes data that includes proliferation-related genes and hormone receptor-related genes, EndoPredict was trained and validated to provide precise assessment of early and late risk for recurrence as well as to determine low or high-risk patients.

The test has been clinically used in more than 13,000 patients.

Myriad discovers and commercialises molecular diagnostic tests to determine the risk of developing disease, diagnose disease, assess the risk of disease progression and guide treatment decisions.

Image: Testing in a lab. Photo: courtesy of Myriad Genetics.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact